Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-IFN alpha-2b and NAs in CHB with or without MASLD
NCT07071636Phase 4Not yet recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoint: HBsAg clearance rate at 48 weeks. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07071636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071636.